Share

December 28, 2004; 63 (12 suppl 6) Articles

Mitoxantrone treatment of multiple sclerosis

Safety considerations

Bruce A. Cohen, Daniel D. Mikol
First published December 28, 2004, DOI: https://doi.org/10.1212/WNL.63.12_suppl_6.S28
Citation
Permissions

Make Comment

See Comments

Downloads
1

Share

Article Information

vol. 63 no. 12 suppl 6 S28-S32
DOI: 
https://doi.org/10.1212/WNL.63.12_suppl_6.S28
PubMed: 
15623667
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 28, 2004.
Copyright & Usage: 
© 2004

Author Disclosures

    1. Bruce A. Cohen, MD and
    2. Daniel D. Mikol, MD, PhD
  1. Bruce A. Cohen, MD and
  2. Daniel D. Mikol, MD, PhD
  1. From the Davee Department of Neurology, Northwestern University, Chicago, Illinois (Dr. Cohen) and the Department of Neurology, University of Michigan, Ann Arbor, Michigan (Dr. Mikol).
  1. Address correspondence and reprint requests to Dr. Bruce A. Cohen, Northwestern University Department of Neurology, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago, IL 60611; e-mail: bac106{at}northwestern.edu
View Full Text

Article usage

Article usage: December 2004 to December 2020

AbstractFullPdfSource
Dec 200410220Highwire
Jan 2005852250Highwire
Feb 2005461710Highwire
Mar 2005291340Highwire
Apr 200514890Highwire
May 200523970Highwire
Jun 200520940Highwire
Jul 200521780Highwire
Aug 200527920Highwire
Sep 200519670Highwire
Oct 200528860Highwire
Nov 200539910Highwire
Dec 200510400Highwire
Jan 200623210Highwire
Feb 200636200Highwire
Mar 200630390Highwire
Apr 200625160Highwire
May 200616180Highwire
Jun 200617250Highwire
Jul 200617180Highwire
Aug 20062490Highwire
Sep 200634110Highwire
Oct 200618150Highwire
Nov 20061090Highwire
Dec 200624280Highwire
Jan 200719200Highwire
Feb 200714130Highwire
Mar 20072580Highwire
Apr 200722120Highwire
May 200728240Highwire
Jun 200742260Highwire
Jul 200734261Highwire
Aug 200741210Highwire
Sep 200727160Highwire
Oct 200729220Highwire
Nov 200720120Highwire
Dec 200730250Highwire
Jan 200835120Highwire
Feb 200823110Highwire
Mar 200832180Highwire
Apr 200839120Highwire
May 200836100Highwire
Jun 20083070Highwire
Jul 200844120Highwire
Aug 200836220Highwire
Sep 20084480Highwire
Oct 200829120Highwire
Nov 200824130Highwire
Dec 20083180Highwire
Jan 200935100Highwire
Feb 20093460Highwire
Mar 200928190Highwire
Apr 200947100Highwire
May 200927100Highwire
Jun 20092280Highwire
Jul 20093170Highwire
Aug 20092650Highwire
Sep 20092690Highwire
Oct 20094190Highwire
Nov 20092760Highwire
Dec 20092750Highwire
Jan 20102150Highwire
Feb 201041100Highwire
Mar 20103220Highwire
Apr 20102660Highwire
May 201020100Highwire
Jun 20101430Highwire
Jul 20101920Highwire
Aug 2010830Highwire
Sep 20102120Highwire
Oct 20102330Highwire
Nov 2010610Highwire
Dec 20103520Highwire
Jan 2011800Highwire
Feb 20111410Highwire
Mar 20111930Highwire
Apr 20112460Highwire
May 20111900Highwire
Jun 20112070Highwire
Jul 20111820Highwire
Aug 20111530Highwire
Sep 20111630Highwire
Oct 20111900Highwire
Nov 20113110Highwire
Dec 20112620Highwire
Jan 20122620Highwire
Feb 20122700Highwire
Mar 20122560Highwire
Apr 20122170Highwire
May 20122700Highwire
Jun 20121800Highwire
Jul 20124500Highwire
Aug 20121300Highwire
Sep 20121310Highwire
Oct 20121010Highwire
Nov 20121700Highwire
Dec 20122540Highwire
Jan 20131700Highwire
Feb 20131300Highwire
Mar 20131500Highwire
Apr 20133200Highwire
May 20131700Highwire
Jun 20132430Highwire
Jul 20131710Highwire
Aug 2013400Highwire
Sep 20131510Highwire
Oct 20131920Highwire
Nov 20134210Highwire
Dec 20132720Highwire
Jan 20141300Highwire
Feb 2014610Highwire
Mar 20141400Highwire
Apr 20142100Highwire
May 2014900Highwire
Jun 20142630Highwire
Jul 20141400Highwire
Aug 20141500Highwire
Sep 2014800Highwire
Oct 20141310Highwire
Nov 2014800Highwire
Dec 2014800Highwire
Jan 20151320Highwire
Feb 20151010Highwire
Mar 2015500Highwire
Apr 2015910Highwire
May 2015600Highwire
Jun 20151300Highwire
Jul 20154000Highwire
Aug 20151720Highwire
Sep 2015700Highwire
Oct 20151500Highwire
Nov 20151400Highwire
Dec 20151110Highwire
Jan 2016800Highwire
Feb 2016710Highwire
Mar 20162300Highwire
Apr 20161200Highwire
May 2016600Highwire
Jun 20161010Highwire
Jul 2016310Highwire
Aug 20161500Highwire
Sep 2016800Highwire
Oct 20163600Highwire
Nov 20161500Highwire
Dec 2016810Highwire
Jan 2017600Highwire
Feb 20171130Highwire
Mar 20171400Highwire
Apr 2017100Highwire
May 20171000Highwire
Jun 2017300Highwire
Jul 20171020Highwire
Aug 20171200Highwire
Sep 2017700Highwire
Oct 2017810Highwire
Nov 2017510Highwire
Dec 2017710Highwire
Jan 2018620Highwire
Feb 2018410Highwire
Mar 2018410Highwire
Apr 2018700Highwire
May 2018500Highwire
Jun 20181310Highwire
Jul 20181560Highwire
Aug 2018900Highwire
Sep 2018500Highwire
Oct 20181200Highwire
Nov 20182510Highwire
Dec 20181300Highwire
Jan 20191500Highwire
Feb 2019800Highwire
Mar 20191810Highwire
Apr 20191610Highwire
May 20191200Highwire
Jun 20191320Highwire
Jul 2019600Highwire
Aug 2019610Highwire
Sep 2019310Highwire
Oct 2019900Highwire
Nov 2019800Highwire
Dec 20191740Highwire
Jan 20202200Highwire
Feb 2020500Highwire
Mar 2020300Highwire
Apr 2020700Highwire
May 20201330Highwire
Jun 20204000Highwire
Jul 2020800Highwire
Aug 2020700Highwire
Sep 2020620Highwire
Oct 20201600Highwire
Nov 20203110Highwire
Dec 20201400Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

  • Reply to Pratt et al
    • Bruce A. Cohen M.D., Davee Dept of Neurology, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago Illinois 60611
    • Daniel D. Mikol, M.D. Ph.D
    Submitted June 07, 2005
  • Mitoxantrone treatment of multiple sclerosis: Safety considerations
    • Robert G. Pratt, PharmD, FDA, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-430 Rockville, MD 20857
    • Gerard A. Boehm, MD, MPH, Cindy M. Kortepeter, PharmD, Judith A. Racoosin, MD, MPH
    Submitted June 07, 2005
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me